TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression.

TMPRSS2-Ets gene fusions were identified in prostate cancers where the promoter of transmembrane protease, serine 2 (TMPRSS2) fused with coding sequence of the erythroblastosis virus E26 (Ets) gene family members. TMPRSS2 is an androgen responsive transmembrane serine protease. Ets family members are oncogenic transcription factors that contain a highly conserved Ets DNA binding domain and an N-terminal regulatory domain.Fusion of these gene results in androgen dependent transcription of Ets factor in prostate tumor cells. The ERG is the most common fusion partner with TMPRSS2 promoter in prostate cancer patients. The high prevalence of these gene fusions, in particular TMPRSS2-ERG, makes them attractive as potential diagnostic and prognostic indicators, as well as making them a potential target for tailored therapies.This review focuses on the clinical and biological significance of TMPRSS2-ERG fusions and their role in PC development and progression.

[1]  D. Stéhelin,et al.  Erg, an Ets-family member, differentially regulates human collagenase1 (MMP1) and stromelysin1 (MMP3) gene expression by physically interacting with the Fos/Jun complex. , 1996, Oncogene.

[2]  D. Stéhelin,et al.  The Ets Transcription Factors Interact with Each Other and with the c-Fos/c-Jun Complex via Distinct Protein Domains in a DNA-dependent and -independent Manner* , 1997, The Journal of Biological Chemistry.

[3]  D. Stéhelin,et al.  Erg proteins, transcription factors of the Ets family, form homo, heterodimers and ternary complexes via two distinct domains , 1998, Oncogene.

[4]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .

[5]  M. Duterque-Coquillaud,et al.  When Ets transcription factors meet their partners. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[6]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[7]  A. Evans,et al.  Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. , 2006, Neoplasia.

[8]  O. Kallioniemi,et al.  TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. , 2006, Cancer research.

[9]  I. Panagopoulos,et al.  Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. , 2006, Genes, chromosomes & cancer.

[10]  Arul M Chinnaiyan,et al.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. , 2006, Cancer research.

[11]  Michael Ittmann,et al.  Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.

[12]  I. Panagopoulos,et al.  Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer , 2006 .

[13]  G. Jenster,et al.  TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. , 2006, Cancer research.

[14]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.

[15]  Debashis Ghosh,et al.  Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer , 2007, Modern Pathology.

[16]  J. Damber,et al.  Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. , 2007, Oncology reports.

[17]  L. Klotz,et al.  Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression , 2007, Cancer biology & therapy.

[18]  M. Rubin,et al.  Morphological features of TMPRSS2–ERG gene fusion prostate cancer , 2007, The Journal of pathology.

[19]  Y Pawitan,et al.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.

[20]  Yao-Tseng Chen,et al.  Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues , 2007, Modern Pathology.

[21]  J. Trachtenberg,et al.  Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer , 2007, British Journal of Cancer.

[22]  J. Tchinda,et al.  Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. , 2007, Neoplasia.

[23]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[24]  R. Eeles,et al.  Diversity of TMPRSS2-ERG fusion transcripts in the human prostate , 2007, Oncogene.

[25]  M. Gleave,et al.  Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer , 2008, BMC Cancer.

[26]  Chen Sun,et al.  Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer , 2008, Clinical Cancer Research.

[27]  S. Srivastava,et al.  TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation , 2008, Oncogene.

[28]  S. Srivastava,et al.  Mapping of TMPRSS2–ERG fusions in the context of multi-focal prostate cancer , 2008, Modern Pathology.

[29]  T. Tammela,et al.  TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis , 2008, Clinical Cancer Research.

[30]  J Cuzick,et al.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.

[31]  R. Shah,et al.  Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.

[32]  M. Gleave,et al.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.

[33]  P. Nelson,et al.  A causal role for ERG in neoplastic transformation of prostate epithelium , 2008, Proceedings of the National Academy of Sciences.

[34]  R. Shah,et al.  CHARACTERIZATION OF TMPRSS2-ETS GENE ABERRATIONS IN ANDROGEN INDEPENDENT METASTATIC PROSTATE CANCER , 2008 .

[35]  S. Varambally,et al.  Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. , 2008, Cancer research.

[36]  M. Ittmann,et al.  Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. , 2008, Cancer research.

[37]  S. Dhanasekaran,et al.  A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. , 2008, Cancer research.

[38]  G. Jenster,et al.  Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. , 2008, Cancer research.

[39]  O. Ludkovski,et al.  Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome , 2008, Modern Pathology.

[40]  J. Amiel,et al.  Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. , 2008, Cancer genetics and cytogenetics.

[41]  S. Varambally,et al.  Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer , 2009, Science.

[42]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[43]  A. Haese*,et al.  TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[44]  Jie Zhang,et al.  Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in Cancer , 2009, Cell.

[45]  D. Dearnaley,et al.  Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. , 2009, Cancer research.

[46]  W. Gerald,et al.  TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. , 2009, Cancer research.

[47]  Arul M Chinnaiyan,et al.  Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States , 2009, Clinical Cancer Research.

[48]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[49]  M. Teitell,et al.  ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells , 2009, Proceedings of the National Academy of Sciences.

[50]  E. Baldi,et al.  Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: Preliminary results , 2009, Journal of endocrinological investigation.

[51]  G. Jenster,et al.  Overexpression of Prostate-Specific TMPRSS2(exon 0)-ERG Fusion Transcripts Corresponds with Favorable Prognosis of Prostate Cancer , 2009, Clinical Cancer Research.

[52]  S. Balk,et al.  Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. , 2009, Cancer research.

[53]  M. Gerstein,et al.  N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. , 2009, Neoplasia.

[54]  C. LaFargue,et al.  TMPRSS2-ERG fusion is frequently observed in gleason pattern 3 prostate cancer in a Canadian cohort , 2009, Cancer biology & therapy.

[55]  M. Rubin,et al.  Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer. , 2009, Cancer research.

[56]  W. Isaacs,et al.  TMPRSS2–ERG gene fusion status in minute (minimal) prostatic adenocarcinoma , 2009, Modern Pathology.

[57]  C. Sander,et al.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis , 2009, Nature Genetics.

[58]  B. Leyland-Jones,et al.  Prostate cancer genes associated with TMPRSS2–ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts , 2010, British Journal of Cancer.

[59]  E. Baldi,et al.  TMPRSS2:ERG fusion gene and androgen-ablation therapy in prostate cancer. , 2010, Archives of pathology & laboratory medicine.

[60]  D. Berney,et al.  Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. , 2010, Cancer research.

[61]  S. Sheng,et al.  Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERG Fusion-Positive Prostate Cancer Cells. , 2010, Translational oncology.

[62]  M. Rubin,et al.  Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort , 2009, Modern Pathology.

[63]  W. Gerald,et al.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer , 2010, British Journal of Cancer.

[64]  S. Srivastava,et al.  Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells Reflects TMPRSS2-ERG Fusion Status , 2009, Prostate Cancer and Prostatic Diseases.

[65]  M. Rubin,et al.  ERG rearrangement metastasis patterns in locally advanced prostate cancer. , 2010, Urology.

[66]  M. Rubin,et al.  ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. , 2010, Neoplasia.

[67]  Zhaohui S. Qin,et al.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.

[68]  A. D. De Marzo,et al.  Transcription-Induced DNA Double Strand Breaks: Both Oncogenic Force and Potential Therapeutic Target? , 2011, Clinical Cancer Research.

[69]  S. Srivastava,et al.  ERG oncogene modulates prostaglandin signaling in prostate cancer cells , 2011, Cancer biology & therapy.

[70]  Wei Yan,et al.  Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. , 2011, Cancer cell.

[71]  M. Ittmann,et al.  Role of TMPRSS2-ERG Gene Fusion in Negative Regulation of PSMA Expression , 2011, PloS one.

[72]  A. Villers,et al.  Abnormal Expression of the ERG Transcription Factor in Prostate Cancer Cells Activates Osteopontin , 2011, Molecular Cancer Research.

[73]  M. Gleave,et al.  Insulin increases de novo steroidogenesis in prostate cancer cells. , 2011, Cancer research.

[74]  V. Rotter,et al.  TMPRSS2/ERG Promotes Epithelial to Mesenchymal Transition through the ZEB1/ZEB2 Axis in a Prostate Cancer Model , 2011, PloS one.

[75]  Arul M Chinnaiyan,et al.  Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. , 2011, Neoplasia.

[76]  S. Varambally,et al.  TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. , 2011, Cancer research.